Cite
HARVARD Citation
Usmani, S. et al. (2021). Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial. Lancet. 8 (1), pp. e45-e54. [Online].